Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor.

[1]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[2]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[3]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[4]  L. Emens.  Trastuzumab: Targeted Therapy for the Management of HER-2/neu-Overexpressing Metastatic Breast Cancer , 2005, American journal of therapeutics.

[5]  A. Chang,et al.  Immunologic response to cryoablation of breast cancer , 2005, Breast Cancer Research and Treatment.

[6]  A. Chang,et al.  Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. , 2005, Cancer research.

[7]  R. Simmons,et al.  Cryoablation of Early-Stage Breast Cancer: Work-in-Progress Report of a Multi-Institutional Trial , 2004, Annals of Surgical Oncology.

[8]  R. Simmons,et al.  Ablative techniques in the treatment of benign and malignant breast disease. , 2003, Journal of the American College of Surgeons.

[9]  Fumito Ito,et al.  Antitumor Reactivity of Anti-CD3/Anti-CD28 Bead-Activated Lymphoid Cells: Implications for Cell Therapy in a Murine Model , 2003, Journal of immunotherapy.

[10]  D. Amadori,et al.  Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma , 2003, Journal of immunotherapy.

[11]  P. Dalerba,et al.  Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.

[12]  B. Dréno,et al.  Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma , 2002, Cancer Immunology, Immunotherapy.

[13]  B. Dréno,et al.  Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients , 2002, Cancer Immunology, Immunotherapy.

[14]  W. Alvord,et al.  Adoptive Cellular Therapy With Tumor Vaccine Draining Lymph Node Lymphocytes After Vaccination With HLA-B7/&bgr;2-Microglobulin Gene-Modified Autologous Tumor Cells , 2002, Journal of immunotherapy.

[15]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[16]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[17]  J. Troppmair,et al.  Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status. , 1994, Immunology.

[18]  S. Rosenberg,et al.  Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. , 1988, Cancer research.

[19]  H. Murray.  Interferon-gamma, the activated macrophage, and host defense against microbial challenge. , 1988, Annals of internal medicine.

[20]  W. A. Soanes,et al.  Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. , 1970, The Journal of urology.

[21]  A. Gage.  Cryosurgery for oral and pharyngeal carcinoma. , 1969, American journal of surgery.

[22]  Boris Rubinsky,et al.  Effect of thermal variables on human breast cancer in cryosurgery , 2004, Breast Cancer Research and Treatment.

[23]  S. Edge,et al.  In-situ ablation of breast cancer. , 2001, Breast disease.

[24]  M. Sabel,et al.  Cryosurgery of breast cancer. , 1997, Archives of surgery.

[25]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[26]  G. Onik,et al.  Percutaneous prostate cryoablation , 1995 .

[27]  J. Johnson.  Immunologic aspects of cryosurgery: potential modulation of immune recognition and effector cell maturation. , 1990, Clinics in dermatology.